drugset / Trial / NCT05315128
Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers
RandomizedParallel-groupDouble-blindTreatment
Summary
to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management
Timeline
- Start
- 2020-07-06
- Primary completion
- 2021-08-10
- Completion
- 2021-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Methotrexate | Small molecule | 12.5 mg | Other |
| Comparator | Methotrexate | Small molecule | 25 mg | Other |